Program
Rituximab
Also written as “rituximab”, “rituximab [MabThera/Rituxan]” and “Rituximab SC”.
Its studies are mostly in Arthritis, Rheumatoid · Lymphoma, Non-Hodgkin · Lymphoma, Large B-Cell, Diffuse · Lymphoma, Follicular · Leukemia, Lymphocytic, Chronic, B-Cell, led by 20 companies.
Drug pageRituximab: every studyMany companies study it; this page follows only the 124 they lead. All 1,284 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 781 open or running | phase 4since Jan 18, 2007 | Apr 1, 2003 | none ahead |
| SymBio Pharmaceuticalsits history only | 50 open or running | phase 3since Dec 10, 2017 | Nov 18, 2008 | none ahead |
| AbbVieits history only | 40 open or running | phase 3since Jun 9, 2014 | Apr 20, 2012 | none ahead |
| AstraZenecaits history only | 42 open or running | phase 4since Aug 23, 2023 | Apr 8, 2016 | Oct 31, 2028phase 2 · NCT05951959 |
| Biogenits history only | 40 open or running | phase 4since Aug 23, 2004 | Mar 31, 2003 | none ahead |
| Takedaits history only | 40 open or running | phase 3since Apr 7, 2006 | Jun 11, 2004 | none ahead |
| Biocadits history only | 30 open or running | phase 3since Oct 3, 2012 | Oct 3, 2012 | none ahead |
| Celltrionits history only | 30 open or running | phase 1since Feb 8, 2012 | Feb 8, 2012 | none ahead |
| Favrilleits history only | 30 open or running | phase 3since Aug 4, 2004 | Aug 4, 2004 | none ahead |
| GlaxoSmithKlineits history only | 20 open or running | phase 3since Oct 13, 2017 | Dec 14, 2015 | none ahead |
| ImmunityBioits history only | 22 open or running | phase 1since Oct 19, 2022 | Oct 19, 2022 | Oct 2027phase 1 · NCT06334991 |
| Mabionits history only | 20 open or running | phase 3since Jun 9, 2015 | Jun 9, 2015 | none ahead |
| Merckits history only | 20 open or running | phase 1since May 18, 2011 | May 18, 2011 | none ahead |
| Sarah Cannon Research Instituteits history only | 20 open or running | phase 2since Nov 7, 2005 | Nov 7, 2005 | none ahead |
| Amgenits history only | 10 open or running | phase 2since Jul 5, 2000 | Jul 5, 2000 | none ahead |
| Bayerits history only | 10 open or running | phase 2since Jul 8, 2004 | Jul 8, 2004 | none ahead |
| Mabscaleits history only | 11 open or running | phase 1since Dec 7, 2023 | Dec 7, 2023 | none ahead |
| Pharmatechits history only | 10 open or running | phase 2since Jan 26, 2009 | Jan 26, 2009 | none ahead |
| Probiomed S.A. de C.V.its history only | 10 open or running | phase 3since Jan 8, 2011 | Jan 8, 2011 | none ahead |
| Sinocelltech Groupits history only | 10 open or running | phase 1since Jul 30, 2014 | Jul 30, 2014 | none ahead |
Also a collaborator on its studies: ICON Clinical Research, Johnson & Johnson, Bristol-Myers Squibb, Merck KGaA, Darmstadt, Germany, UCB, Eli Lilly, Teva Pharmaceutical Industries, Roche Pharma and Chiron.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Hoffmann-La Roche only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 44 studies since Jan 31, 2007.
- Mar 4, 20142 phase 3 studies in Arthritis, RheumatoidNCT02079532, NCT02097745
- Mar 19, 2014Phase 2 study in Arthritis, RheumatoidNCT02093026 · 465 enrolled · United States, Australia, Belgium and more
- Apr 14, 2014Phase 4 study in Granulomatosis with PolyangiitisNCT02115997 · 30 enrolled · India
- Oct 2, 2014Phase 2 study in LymphomaNCT02257567 · 331 enrolled · United States, Australia, Canada and more
- Mar 4, 20152 phase 3 studiesNCT02383589, NCT02406092
- Aug 24, 2015Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT02533401 · 34 enrolled · Argentina, Venezuela
- Sep 23, 2015Phase 3 study in Lymphoma, FollicularNCT02569996 · 124 enrolled · Hungary
- Nov 3, 2015Phase 2 study in RecurrenceNCT02600897 · 114 enrolled · United States, Spain, United Kingdom
- Feb 23, 2016Phase 2 study in Arthritis, RheumatoidNCT02693210 · 161 enrolled · Australia, Belgium, Canada and more
- Jul 22, 2019Phase 1 study in Multiple MyelomaNCT04045028 · 41 enrolled · United States, Korea, Republic of
- Nov 25, 2020Phase 2 study in Lymphoma, Large B-Cell, DiffuseNCT04660799 · 50 enrolled · China
- Jan 13, 2021Phase 3 study in RecurrenceNCT04712097 · 478 enrolled · United States, Australia, Brazil and more
- Mar 8, 2021Phase 1 study in Lymphoma, Large B-Cell, DiffuseNCT04790903 · 50 enrolled · United States, France, Italy and more
- May 3, 2022Phase 1 study in Lymphoma, Large B-Cell, DiffuseNCT05364424 · 43 enrolled · United States
- Jan 29, 2026Named rituximabINNProposed as its International Nonproprietary Name in WHO's List 134 · before, MK-8808
TargetBeta
“A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes”NCIt, by rule
“B-lymphocyte antigen CD20 binding agent”ChEMBL 37, by rule
Other programs on MS4A1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ocrelizumabrule | Hoffmann-La Roche | phase 4 | 42 |
| obinutuzumabrule | Hoffmann-La Roche | phase 4 | 42 |
| ublituximabrule | TG Therapeutics | phase 3 | 23 |
| mosunetuzumabrule | Hoffmann-La Roche | phase 3 | 14 |
| glofitamabrule | Hoffmann-La Roche | phase 3 | 13 |
| epcoritamabrule | Genmab | phase 3 | 13 |
| Anti-CD20 Monoclonal Antibody MIL62rule | beijing-mabworks-biotech-co-ltd | phase 3 | 10 |
| odronextamabrule | Regeneron Pharmaceuticals | phase 3 | 8 |
| TQB2825 | Sino Biopharmaceutical | phase 3 | 5 |
| zuberitamabrule | bioray-pharmaceutical-co-ltd | phase 3 | 3 |
| rondecabtagene autoleucelrule | lyell-immunopharma-inc | phase 3 | 2 |
| zamtocabtagene autoleucelrule | miltenyi-biomedicine-gmbh | phase 2 | 8 |
Studies
The newest 60 of 78 Hoffmann-La Roche leads. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05364424Lymphoma, Large B-Cell, Diffuse · United States | 1 | Completed | Oct 15, 2025 | 43 |
| NCT04790903Lymphoma, Large B-Cell, Diffuse · United States, France, Italy and more | 1 | Terminated | May 21, 2024 | 50 |
| NCT04712097Recurrence · United States, Australia, Brazil and more | 3 | Active, not recruiting | Jun 3, 2026 | 478 |
| NCT04660799Lymphoma, Large B-Cell, Diffuse · China | 2 | Completed | May 23, 2022 | 50 |
| NCT04045028Multiple Myeloma · United States, Korea, Republic of | 1 | Terminated | Mar 28, 2023 | 41 |
| NCT02693210Arthritis, Rheumatoid · Australia, Belgium, Canada and more | 2 | Completed | Aug 2002 | 161 |
| NCT02600897Recurrence · United States, Spain, United Kingdom | 2 | Completed | Dec 15, 2021 | 114 |
| NCT02569996Lymphoma, Follicular · Hungary | 3 | Completed | Aug 2013 | 124 |
| NCT02533401Leukemia, Lymphocytic, Chronic, B-Cell · Argentina, Venezuela | 2 | Completed | Dec 2014 | 34 |
| NCT02406092Lymphoma, Non-Hodgkin · Algeria, Morocco, Tunisia | 3 | Completed | Jun 30, 2021 | 139 |
| NCT02383589Pemphigus · United States, Argentina, Australia and more | 3 | Completed | Nov 28, 2018 | 135 |
| NCT02257567Lymphoma · United States, Australia, Canada and more | 2 | Completed | Oct 21, 2021 | 331 |
| NCT02115997Granulomatosis with Polyangiitis · India | 4 | Completed | Jun 7, 2022 | 30 |
| NCT02097745Arthritis, Rheumatoid · United States, Belgium, Canada and more | 3 | Completed | Jun 2013 | 341 |
| NCT02093026Arthritis, Rheumatoid · United States, Australia, Belgium and more | 2 | Completed | Dec 2012 | 465 |
| NCT02079532Arthritis, Rheumatoid · Germany | 3 | Completed | Nov 2010 | 302 |
| NCT02055820Lymphoma, Non-Hodgkin · United States, Australia, Austria and more | 2 | Completed | Jun 28, 2017 | 267 |
| NCT02006706Arthritis, Rheumatoid · Serbia | 3 | Completed | Nov 23, 2007 | 15 |
| NCT02013817Leukemia, Lymphocytic, Chronic, B-Cell · Austria | 2 | Completed | Sep 24, 2012 | 43 |
| NCT01998893Lymphoma, Non-Hodgkin · Germany | 2 | Completed | Feb 2008 | 38 |
| NCT01987505Lymphoma, Non-Hodgkin · Spain | 3 | Completed | Apr 11, 2017 | 140 |
| NCT01889069Lymphoma · Italy | 3 | Completed | May 28, 2019 | 159 |
| NCT01750697Granulomatosis with Polyangiitis · United States, Canada, France and more | 2 | Completed | May 10, 2018 | 25 |
| NCT01724021Lymphoma, Large B-Cell, Diffuse · Argentina, Australia, Austria and more | 3 | Completed | Jan 2015 | 743 |
| NCT01671904Leukemia, Lymphocytic, Chronic, B-Cell · United States, France, Germany | 1 | Completed | Aug 17, 2018 | 84 |
| NCT01649856Lymphoma, Large B-Cell, Diffuse · Algeria, Argentina, Belgium and more | 3 | Completed | Oct 21, 2014 | 572 |
| NCT01461928Lymphoma, Non-Hodgkin · Albania, Argentina, Austria and more | 3 | Completed | Jun 2, 2018 | 692 |
| NCT01392716Lymphoma, Non-Hodgkin · France | 2 | Completed | Feb 2006 | 48 |
| NCT01388959Lymphoma, Non-Hodgkin · France | 2 | Completed | Apr 2004 | 40 |
| NCT01382940Arthritis, Rheumatoid · United States | 4 | Completed | Jan 6, 2013 | 351 |
| NCT01272908Arthritis, Rheumatoid · Canada, Sweden | 3 | Completed | Mar 12, 2009 | 120 |
| NCT01271010Leukemia, Lymphocytic, Chronic, B-Cell · Russian Federation | 4 | Terminated | May 4, 2016 | 89 |
| NCT01263704Leukemia, Lymphocytic, Chronic, B-Cell · Israel | 2 | Completed | Apr 3, 2017 | 42 |
| NCT01200758Lymphoma, Non-Hodgkin · Australia, Belgium, Bosnia and Herzegovina and more | 3 | Completed | Jun 12, 2012 | 410 |
| NCT01153971Lymphoma, Non-Hodgkin · Italy | 2 | Completed | Sep 24, 2010 | 47 |
| NCT01144403Lymphoma, Large B-Cell, Diffuse · Romania | 2 | Terminated | Aug 2014 | 8 |
| NCT01144364Lymphoma, Non-Hodgkin · Italy | 3 | Completed | Jul 21, 2011 | 234 |
| NCT01126541Arthritis, Rheumatoid · France | 3 | Completed | Nov 2011 | 224 |
| NCT01117129Arthritis, Rheumatoid · Spain | 4 | Terminated | Jun 2010 | 2 |
| NCT01087151Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Brazil and more | 2 | Completed | Jun 2012 | 118 |
| NCT00930514Lymphoma, Follicular · Argentina, Australia, Brazil and more | 1 | Completed | Jul 2013 | 281 |
| NCT00845832Arthritis, Rheumatoid · France, Germany, Greece and more | 2 | Terminated | Mar 2013 | 24 |
| NCT00770562Purpura, Thrombocytopenic, Idiopathic · Italy | 3 | Completed | Jul 2008 | 103 |
| NCT00719472Lymphoma, Non-Hodgkin | 3 | Completed | May 2011 | 451 |
| NCT00718549Leukemia, Lymphocytic, Chronic, B-Cell · Belarus, Poland | 3 | Completed | Sep 14, 2015 | 128 |
| NCT00578305Arthritis, Rheumatoid · Argentina, Brazil, Canada and more | 3 | Completed | Nov 2009 | 185 |
| NCT00576433Arthritis, Rheumatoid · Russian Federation | 4 | Completed | Nov 2010 | 60 |
| NCT00545714Leukemia, Lymphocytic, Chronic, B-Cell · Spain | 2 | Completed | May 20, 2016 | 86 |
| NCT00532129Leukemia, Lymphocytic, Chronic, B-Cell · United Kingdom | 2 | Completed | Apr 2012 | 100 |
| NCT00517699Lymphoma · Canada | 2 | Terminated | Mar 2009 | 5 |
| NCT00503425Arthritis, Rheumatoid · Israel | 3 | Completed | May 26, 2013 | 215 |
| NCT00502996Arthritis, Rheumatoid · Argentina, Brazil, Chile and more | 3 | Completed | Dec 2008 | 246 |
| NCT00502853Arthritis, Rheumatoid · Italy | 4 | Completed | Jul 23, 2010 | 10 |
| NCT00502840Arthritis, Rheumatoid · Germany | 3 | Completed | Sep 20, 2011 | 193 |
| NCT00475423Purpura, Thrombocytopenic, Idiopathic · Australia | 2 | Completed | Aug 2011 | 122 |
| NCT00472420Lymphoma, Mantle-Cell · Hungary | 2 | Completed | May 25, 2011 | 48 |
| NCT00468546Arthritis, Rheumatoid · United States, Belgium, Canada and more | 3 | Completed | Jan 2005 | 520 |
| NCT00462345Arthritis, Rheumatoid · Korea, Republic of | 4 | Completed | Jul 2009 | 40 |
| NCT00443651Arthritis, Rheumatoid | 3 | Completed | May 2011 | 578 |
| NCT00430352Lymphoma, Non-Hodgkin · Albania, Argentina, Australia and more | 4 | Completed | May 26, 2011 | 545 |
How it is read
Names in the registry
- “Rituximab”, 104 entries
- “rituximab”, 34 entries
- “rituximab [MabThera/Rituxan]”, 23 entries
- “Rituximab SC”, 2 entries
- “MK-8808”, 2 entries
Conditions, from the studies’ own filings
- Arthritis, Rheumatoid, 34 studies
- Lymphoma, Non-Hodgkin, 33 studies
- Lymphoma, Large B-Cell, Diffuse, 23 studies
- Lymphoma, Follicular, 21 studies
- Leukemia, Lymphocytic, Chronic, B-Cell, 18 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.